AMGN
★★☆☆☆ PasstemplateAmgen Inc.
Healthcare · sector percentile 92
세션 움직임
$413.08
거래량 0.71× 평균
64/100 quant · tgt $390.94
RS60 +7.7% vs SPY · ADV$ 1255.6M
세션 2026-10-07 · 스냅샷 — 실시간 호가 아님
직전 스캔 대비
2026-10-06 → 2026-10-07
참고용이며 매수/매도 신호가 아닙니다. 스캔 이력과 캐시된 뉴스·공시로 구성됩니다.
스냅샷 시세
세션 2026-10-07 · 스캔 2026-10-07 · 푸시 10-07 13:51 ET · 정규장 (오래됨)
시세 상세 보기시세 상세 숨기기
- 종가/스캔가
- $402.60
- 전일 종가
- $402.60
- 푸시 최신가
- $413.51 (오래됨) · 10-07 13:51 ET · 정규장
- 세션 시가
- $403.06
- 직전 세션 범위
- $401.85 – $415.79
- 52주 범위
- $281.86 – $447.03
- 세션 거래량
- 2,218,937
- 평균 거래량 (20일)
- 3,125,582
- 시가총액
- $217.66B
- PER (TTM)
- 25.01
- Forward PER
- 16.45
- 배당 수익률
- 2.43%
- 1년 목표가 추정
- $390.94
- 다음 실적
- 2026-11-03
Snapshot quote — last daily session bars and scan fundamentals. Not live bid/ask or intraday quotes.
$1,000.00 넣었다면 지금
1년 전
$1,428.14
+43%
5년 전
$2,296.31
+130%
Price path only from cached daily closes (adjusted when available). Not dividends cash, fees, or advice.
시장 브리핑
선별된 요약입니다 — 매매 신호가 아닙니다. 헤드라인·링크는 제공된 그대로 표시됩니다.
- Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)?
On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints […]
Yahoo · 2026-09-09
- What Eli Lilly Was Telling You While It Rationed Its Own Launches
Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.
Yahoo · 2026-09-09
- AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m. ET on Tuesday, September 15, 2026. Jay Bradner, executive vice president, Research and Development, Artificial Intelligence and Data at Amgen, and Thomas Dittrich, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and th
Yahoo · 2026-09-09
Price Chart
Daily prices from cache
Loading price history…
AI Analysis
- Bull Thesis — AMGN scores 64.45/100 (Pass) with revenue growth at 9.5% and a multi-factor profile supporting the current ranking.
- Risks — Key risks for AMGN include valuation compression, sector rotation, and any deterioration in earnings momentum or balance-sheet leverage. Context: cached next earnings 2026-11-03.
- Target Upside — Consensus implied upside is -2.9%. Category 'Pass' suggests monitoring position sizing against the 100-point model thresholds.
Score History
30 days of scans. Daily batch adds the next weekday automatically while the API is running.
- DatePriceChgScoreRating
- 2026-10-07$402.60−$0.3864.5Pass
- 2026-10-06$402.98−$0.0664.3Pass
- 2026-10-05$403.04−$4.2364.4Pass
- 2026-10-02$407.27−$14.2463.9Pass
- 2026-10-01$421.51−$2.1367.0Pass
- 2026-09-30$423.64+$5.5167.1Pass
- 2026-09-29$418.13+$3.5266.7Pass
- 2026-09-28$414.61+$8.5766.6Pass
- 2026-09-25$406.04−$0.0566.7Pass
- 2026-09-24$406.09−$4.1567.4Pass
- 2026-09-23$410.24+$17.0866.8Pass
- 2026-09-22$393.16+$7.5166.8Pass
- 2026-09-21$385.65+$5.8767.4Pass
- 2026-09-18$379.78+$3.4366.8Pass
- 2026-09-17$376.35+$0.7066.1Pass
- 2026-09-16$375.65−$5.8565.3Pass
- 2026-09-15$381.50+$4.1565.1Pass
- 2026-09-14$377.35−$5.1265.1Pass
- 2026-09-11$382.47−$8.8066.8Pass
- 2026-09-10$391.27−$1.9067.3Pass
- 2026-09-09$393.17−$44.0667.4Pass
- 2026-09-08$437.23$0.0069.1Pass
- 2026-09-07$437.23−$6.8969.1Pass
- 2026-09-04$444.12+$1.2869.2Pass
- 2026-09-03$442.84+$4.7269.2Pass
- 2026-09-02$438.12+$8.2468.7Pass
- 2026-09-01$429.88−$2.5469.5Pass
- 2026-08-31$432.42−$4.5769.6Pass
- 2026-08-28$436.99−$3.3569.0Pass
- 2026-08-27$440.34—69.4Pass
Quant Breakdown
Short volume (FINRA)
Off-exchange short sale volume ratio vs recent sessions — not a squeeze forecast.
- Short / total
- 48.5%
- vs 20d (z)
- -0.44
- Short vol
- 317,153
- Status
- ok
Squeeze pressure score
full25/100
- Short leg
- 10
- Call leg
- 56
- Activity
- 0.2
- Call vol share
- 61.6%
- PCR (vol)
- 0.62
- Call OI share
- 48.8%
- ATM IV
- 35.4%
FINRA off-exchange short volume (TRF/ADF consolidated). Not short interest as % of float. Squeeze pressure score (0–100) — free composite of off-exchange short volume and (when available) call-side options activity. Not a probability that a squeeze will occur.
공시 점수 (Disclosure)
캐시된 SEC 공시 기반 News / Insider / Earnings 규칙 다리 — 참고용이며, beat/miss나 매수 신호가 아닙니다.
점수 창에 최근 SEC 공시·실적 일정 입력이 아직 없습니다.
Disclosure event score — rule-based view of recent SEC filings and earnings calendar. Not a prediction that price will move, and not earnings beat/miss.
실적 서프라이즈 (퀀트 맥락)
최근 퀀트 스캔에 캐시된 Yahoo/공개 펀더멘털 수치입니다 — 공시 이벤트 점수에 합산되지 않으며 매수 신호가 아닙니다. 최신 발표보다 늦을 수 있습니다.
최근 보고 서프라이즈 +0.7%
Filings & events
Recent SEC disclosures and earnings dates — context only, not a trade signal.
- Next earnings
- 2026-11-03yahoo_calendar
- Last earnings
- —
- SEC ↗42026-08-13
PRIMARY DOCUMENT
- SEC ↗42026-08-12
PRIMARY DOCUMENT
- SEC ↗42026-08-10
PRIMARY DOCUMENT
- SEC ↗42026-08-10
PRIMARY DOCUMENT
- SEC ↗42026-08-10
PRIMARY DOCUMENT
- SEC ↗42026-08-07
PRIMARY DOCUMENT
- SEC ↗42026-08-07
PRIMARY DOCUMENT
- SEC ↗10-Q2026-08-05
10-Q
- SEC ↗8-K2026-08-04
8-K
- SEC ↗8-K2026-07-31
8-K
SEC filings as reported; earnings dates may come from Yahoo calendar. Context only — not investment advice and not a prediction that price will move on a filing or event.